Login to Your Account

Eyes on Laquinimod, Others at AAN

BG-12 Positive in First Phase III; Biogen Poised for Oral MS Entry

By Jennifer Boggs

Tuesday, April 12, 2011
Biogen Idec Inc.'s immune modulator BG-12 (dimethyl fumarate) yielded better-than-expected top-line data in its first Phase III trial, news that bodes well for the Cambridge, Mass.-based firm's foray into the oral multiple sclerosis (MS) drug market and may help stave off competitive threats to its lucrative MS franchise.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription